Differential effects of oral versus transdermal estrogen replacement therapy on C-reactive protein in postmenopausal women

Journal of the American College of Cardiology

Volumn 41, Issue 8, 2003, Pages 1358-1363

  Vongpatanasin, Wanpen ^a   Tuncel, Meryem ^a   Wang, Zhongyun ^a   Arbique, Debbie ^a   Mehrad, Borna ^a   Jialal, Ishwarlal ^b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN ANTAGONIST; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; CONJUGATED ESTROGEN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ESTRADIOL; ESTROGEN; INTERLEUKIN 1BETA; INTERLEUKIN 6; PLACEBO; SOMATOMEDIN; STATINE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG FORMULATION; DRUG METABOLISM; ESTROGEN THERAPY; FEMALE; FIRST PASS EFFECT; HUMAN; INFLAMMATION; LIVER; POSTMENOPAUSE; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

EID: 0037394565     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(03)00156-6     Document Type: Article

References (26)

1. Ridker PM, Hennekens CH, Buring JE, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342:836-43.
2. Cushman M, Legault C, Barrett-Connor E, et al. Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) study. Circulation 1999;100:717-22.
3. Ridker PM, Hennekens CH, Rifai N, et al. Hormone replacement therapy and increased plasma concentration of C-reactive protein. Circulation 1999;100:713-6.
4. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998;280:605-13.
5. The Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33.
6. Lou H, Kodama T, Zhao YJ, et al. Inhibition of transplant coronary arteriosclerosis in rabbits by chronic estradiol treatment is associated with abolition of MHC class II antigen expression. Circulation 1996;94:3355-61.
7. Nunomura W, Takakuwa Y, Higashi T. Changes in serum concentration and mRNA level of rat C-reactive protein. Biochimica Biophysica Acta 1994;1227:74-8.
8. Fleiss JL. Design and Analysis of Clinical Experiments. New York, NY: Wiley, 1986:371.
9. van Baal WM, Kenemans P, van der Mooren MJ, et al. Increased C-reactive protein levels during short-term hormone replacement therapy in healthy postmenopausal women. Thromb Haemost 1999;81:925-8.
10. Giltay EJ, Gooren LJ, Emeis JJ, et al. Oral ethinyl estradiol, but not transdermal 17-beta-estradiol, increases plasma C-reactive protein levels in men. Thromb Haemost 2000;84:359-60.
11. Decensi A, Omodei U, Robertson C, et al. Effect of transdermal estradiol and oral conjugated estrogens on C-reactive protein in retinoid-placebo trial in healthy women. Circulation 2002;106:1224-8.
12. Satter N, Parera M, Small M, et al. Hormone replacement therapy and sensitive C-reactive concentrations in women with type 2 diabetes. Lancet 1999;354:487-8.
13. Wakatsuki A, Okatani Y, Ikenoue N, et al. Effect of medroxyprogesterone acetate on vascular inflammatory markers in postmenopausal women receiving estrogen. Circulation 2002;105:1436-9.
14. Skouby SO, Gram J, Anderson LF, et al. Hormone replacement therapy: estrogen and progestin effects on plasma C-reactive protein concentrations. Am J Obstet Gynecol 2002;186:969-77.
15. Pradhan AD, Manson JE, Rossouw JE, et al. Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women's Health Initiative observational study. JAMA 2002;288:980-7.
16. Weissberger AJ, Ho KKY, Lazarus L. Contrasting effects of oral and transdermal routes of estrogen replacement therapy on 24-hour growth hormone (GH) secretion, insulin-like growth factor 1, and GH-binding protein in postmenopausal women. J Clin Endocrinol Metab 1991;72:374-81.
17. Sesmilo G, Biller BM, Llevadot J, et al. Effects of growth hormone administration on inflammatory and other cardiovascular risk markers in men with growth hormone deficiency: a randomized, controlled clinical trial. Ann Intern Med 2000;133:111-22.
18. Jeschke MG, Barrow RE, Herndon DN. Insulin-like growth factor 1 plus insulin-like growth factor binding protein 3 attenuates the proinflammatory acute phase response in severely burned children. Ann Surg 2000;231:246-52.
19. Sesmilo G, Miller KK, Hayden D, et al. Inflammatory cardiovascular risk markers in women with hypopituitarism. J Clin Endocrinol Metab 2002;86:5774-81.
20. Sesmilo G, Fairfield WP, Katznelson L, et al. Cardiovascular risk factors in acromegaly before and after normalization of serum IGF-1 levels with the GH antagonist pegvisomant. J Clin Endocrinol Metab 2002;87:1692-9.
21. Venugopal SM, Devaraj S, Yuhanna I, et al. Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation 2002;106:1439-41.
22. Verma S, Wang C-H, Li S-H, et al. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation 2002;106:913-9.
23. Torzewski M, Rist C, Mortensen RF, et al. C-reactive protein in the arterial intima: role of C-reactive protein receptor-dependent monocyte recruitment in atherogenesis. Arterioscler Thromb Vasc Biol 2000;29:2094-9.
24. Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000;102:2165-8.
25. Ridker PM, Rifai N, Rose L, et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002;347:1557-65.
26. Herrington D, Reboussin DM, Broshinan B, et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 2000;343:522-9.